New antibody WIN378 aims to tame COPD lung inflammation
NCT ID NCT07646587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a new medicine called WIN378 for people with moderate to severe COPD. WIN378 is a long-acting antibody that blocks a protein involved in lung inflammation. The study will test different doses in 105 adults who are former smokers and already on standard triple therapy, to see if it is safe and helps control COPD.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WIN378 (a long-acting antibody that blocks a protein called TSLP to reduce lung inflammation)
What this could lead to
If successful, this could lead to a new, longer-lasting treatment option for people with moderate to severe COPD, helping to control symptoms and reduce flare-ups.
What could go wrong
This is an early phase 2 trial with only 105 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
WB Contracted Clinical Research Site
RECRUITINGMiami Lakes, Florida, 33014, United States
-
WB Contracted Clinical Research Site
RECRUITINGNorth Dartmouth, Massachusetts, 02747, United States
-
WB Contracted Clinical Research Site
RECRUITINGCharlotte, North Carolina, 28277, United States
-
WB Contracted Clinical Research Site
RECRUITINGMcKinney, Texas, 75069, United States